Literature DB >> 33431669

Modulation of immune cell reactivity with cis-binding Siglec agonists.

Corleone S Delaveris1,2, Shannon H Chiu1,2, Nicholas M Riley1, Carolyn R Bertozzi3,2,4.   

Abstract

Inflammatory pathologies caused by phagocytes lead to numerous debilitating conditions, including chronic pain and blindness due to age-related macular degeneration. Many members of the sialic acid-binding immunoglobulin-like lectin (Siglec) family are immunoinhibitory receptors whose agonism is an attractive approach for antiinflammatory therapy. Here, we show that synthetic lipid-conjugated glycopolypeptides can insert into cell membranes and engage Siglec receptors in cis, leading to inhibitory signaling. Specifically, we construct a cis-binding agonist of Siglec-9 and show that it modulates mitogen-activated protein kinase (MAPK) signaling in reporter cell lines, immortalized macrophage and microglial cell lines, and primary human macrophages. Thus, these cis-binding agonists of Siglecs present a method for therapeutic suppression of immune cell reactivity.

Entities:  

Keywords:  Siglec; glycocalyx; glycopolymer; immunotherapy; inflammation

Mesh:

Substances:

Year:  2021        PMID: 33431669      PMCID: PMC7826350          DOI: 10.1073/pnas.2012408118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  70 in total

Review 1.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

2.  Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.

Authors:  T Angata; A Varki
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

3.  Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.

Authors:  Yuzuru Ikehara; Sanae Kabata Ikehara; James C Paulson
Journal:  J Biol Chem       Date:  2004-08-03       Impact factor: 5.157

Review 4.  CD22 as a target of passive immunotherapy.

Authors:  Alessandra Cesano; Urte Gayko
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

5.  Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33.

Authors:  Akiko Ishida; Kaoru Akita; Yugo Mori; Shuhei Tanida; Munetoyo Toda; Mizue Inoue; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2014-07-24       Impact factor: 5.157

6.  Synthesis and biological evaluation of 9-N-oxamyl sialosides as Siglec-7 ligands.

Authors:  Horst Prescher; Stephan Gütgemann; Martin Frank; Elena Kuhfeldt; Carsten Watzl; Reinhard Brossmer
Journal:  Bioorg Med Chem       Date:  2015-07-07       Impact factor: 3.641

7.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Authors:  Thomas Dörner; Joerg Kaufmann; William A Wegener; Nick Teoh; David M Goldenberg; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2006-04-21       Impact factor: 5.156

8.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens.

Authors:  Michael S Haney; Christopher J Bohlen; David W Morgens; James A Ousey; Amira A Barkal; C Kimberly Tsui; Braeden K Ego; Roni Levin; Roarke A Kamber; Hannah Collins; Andrew Tucker; Amy Li; Daan Vorselen; Lorenzo Labitigan; Emily Crane; Evan Boyle; Lihua Jiang; Joanne Chan; Esther Rincón; William J Greenleaf; Billy Li; Michael P Snyder; Irving L Weissman; Julie A Theriot; Sean R Collins; Ben A Barres; Michael C Bassik
Journal:  Nat Genet       Date:  2018-11-05       Impact factor: 38.330

10.  Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.

Authors:  Shaun Spence; Michelle K Greene; François Fay; Emily Hams; Sean P Saunders; Umar Hamid; Marianne Fitzgerald; Jonathan Beck; Baljinder K Bains; Peter Smyth; Efrosyni Themistou; Donna M Small; Daniela Schmid; Cecilia M O'Kane; Denise C Fitzgerald; Sharif M Abdelghany; James A Johnston; Padraic G Fallon; James F Burrows; Daniel F McAuley; Adrien Kissenpfennig; Christopher J Scott
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

View more
  14 in total

1.  Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.

Authors:  Roarke A Kamber; Yoko Nishiga; Bhek Morton; Allison M Banuelos; Amira A Barkal; Felipe Vences-Catalán; Mingxin Gu; Daniel Fernandez; Jose A Seoane; David Yao; Katherine Liu; Sijie Lin; Kaitlyn Spees; Christina Curtis; Livnat Jerby-Arnon; Irving L Weissman; Julien Sage; Michael C Bassik
Journal:  Nature       Date:  2021-09-08       Impact factor: 69.504

2.  Exposure of Keratinocytes to Candida Albicans in the Context of Atopic Milieu Induces Changes in the Surface Glycosylation Pattern of Small Extracellular Vesicles to Enhance Their Propensity to Interact With Inhibitory Siglec Receptors.

Authors:  Adrian Kobiela; Joanna E Frackowiak; Anna Biernacka; Lilit Hovhannisyan; Aleksandra E Bogucka; Kinga Panek; Argho Aninda Paul; Joanna Lukomska; Xinwen Wang; Eleni Giannoulatou; Aleksandra Krolicka; Jacek Zielinski; Milena Deptula; Michal Pikula; Susanne Gabrielsson; Graham S Ogg; Danuta Gutowska-Owsiak
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 3.  The therapeutic potential of sialylated Fc domains of human IgG.

Authors:  Richard J Pleass
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 4.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

5.  Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.

Authors:  Corleone S Delaveris; Aaron J Wilk; Nicholas M Riley; Jessica C Stark; Samuel S Yang; Angela J Rogers; Thanmayi Ranganath; Kari C Nadeau; Catherine A Blish; Carolyn R Bertozzi
Journal:  ChemRxiv       Date:  2020-12-17

Review 6.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

7.  Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.

Authors:  Corleone S Delaveris; Aaron J Wilk; Nicholas M Riley; Jessica C Stark; Samuel S Yang; Angela J Rogers; Thanmayi Ranganath; Kari C Nadeau; Catherine A Blish; Carolyn R Bertozzi
Journal:  ACS Cent Sci       Date:  2021-03-24       Impact factor: 14.553

Review 8.  Siglec Signaling in the Tumor Microenvironment.

Authors:  Eline J H van Houtum; Christian Büll; Lenneke A M Cornelissen; Gosse J Adema
Journal:  Front Immunol       Date:  2021-12-13       Impact factor: 7.561

9.  Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.

Authors:  Itziar Ibarlucea-Benitez; Polina Weitzenfeld; Patrick Smith; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

Review 10.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.